Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 60 mg/ml - injection, solution - excipient ingredients: maltose; human immunoglobulin a; water for injections - intragam p is indicated in replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. indications as at 21 july 2000: replacement igg therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogenic bone marrow transplantation; kawasaki disease. indications as at 25 february 2003: for replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and; congenital acquired immune deficiency syndrome with recurrent infections. for immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp) in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogeneic bone marrow transplantation; kawasaki disease, and; guillain-barre syndrome (gbs).

Malta - anglès - Medicines Authority

kedrion s.p.a loc. ai conti, 55051 castelvecchio pascoli, barga - lucca, italy - human plasma, protein - solution for injection - human plasma protein 100-180 mg - immune sera and immunoglobulins

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

biotest pharma gmbh - human plasma protein; hbs antibodies - solution for infusion - 50 international unit(s)/millilitre - specific immunoglobulins; hepatitis b immunoglobulin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - human plasma protein >90% gamma globulin - pdr+solv for soln for inf - 0.5 g/30 m micromol

Singapur - anglès - HSA (Health Sciences Authority)

eshcol pharmaceutical group singapore pte ltd - human hepatitis b immunoglobulin in 150g/l human plasma protein (igg ≥ 96%) - injection - 500 iu/ml - human hepatitis b immunoglobulin in 150g/l human plasma protein (igg ≥ 96%) 500 iu/ml

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

csl behring gmbh - human plasma protein - solution for injection - 250 international unit(s)/millilitre - specific immunoglobulins; tetanus immunoglobulin

Estats Units - anglès - NLM (National Library of Medicine)

aptevo biotherapeutics llc - human varicella-zoster immune globulin (unii: 33t61iwl27) (human varicella-zoster immune globulin - unii:33t61iwl27) - human varicella-zoster immune globulin 125 [iu] - varizig® [varicella zoster immune globulin (human)] is indicated for post-exposure prophylaxis of varicella in high risk individuals. high risk groups include: - immunocompromised children and adults, - newborns of mothers with varicella shortly before or after delivery, - premature infants, - neonates and infants less than one year of age, - adults without evidence of immunity, - pregnant women. varizig administration is intended to reduce the severity of varicella. administer varizig as soon as possible following varicella zoster virus (vzv) exposure, ideally within 96 hours for greatest effectiveness. - there is no convincing evidence that varizig reduces the incidence of chickenpox infection after exposure to vzv. - there is no convincing evidence that established infections with vzv can be modified by varizig administration. - there is no indication for the prophylactic use of varizig in immunodeficient children or adults when there is a past history of varicella, unless the patient is undergoing bone m

Malta - anglès - Medicines Authority

octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - immunoglobulin g, human - solution for infusion - immunoglobulin g, human 100 mg i/ml - immune sera and immunoglobulins

Malta - anglès - Medicines Authority

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - immunoglobulin tetanus, human - solution for injection - immunoglobulin tetanus, human 250 iu - immune sera and immunoglobulins

Malta - anglès - Medicines Authority

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - immunoglobulin tetanus, human - solution for injection - immunoglobulin tetanus, human 250 iu - immune sera and immunoglobulins